instil bio is a cell therapy company developing tumor infiltrating lymphocytes (til) for the treatment of solid tumor cancers. til are a patient’s own t cells harvested from the patient’s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells. the company is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its lead candidate and a first-in-human study of its next-generation engineered til. the company is led by world-class cell therapy experts and backed by premier global institutional investors. instil is located in the greater los angeles area with additional manufacturing and research facilities in manchester, uk.